ClinicalTrials.gg
CompletedNCT01091103Updated Oct 23, 2018Results posted

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

A Phase 2 interventional study of Enzalutamide in Metastatic Progressive Castration-resistant Prostate Cancer, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
57th of 125
60 · median 52
Started
2010
with 2 others
Phase 2
65 of 125
8 open now
Registered
4th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 57th largest by enrollment, is one of 3 that started in 2010, is one of 65 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.

03

Conditions studied

  • Metastatic Progressive Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed prostate cancer
  • Presence of disease to the bone
  • Ongoing androgen deprivation therapy

Exclusion criteria

Exclusion Criteria:

  • Severe concurrent disease
  • in the brain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Bone Marrow Testosterone

    Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry.

    Time frame: Baseline, Week 9

  2. Change From Baseline in Bone Marrow Dihydrotestosterone

    Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry.

    Time frame: Baseline, Week 9

  3. Change From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status

    Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow testosterone levels at Week 9 was correlated with PSA response status at Week 9.

    Time frame: Baseline, Week 9

  4. Change From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status

    Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow dihydrotestosterone levels at Week 9 was correlated with PSA response status at Week 9.

    Time frame: Baseline, Week 9

Secondary outcomes

  1. Percentage of Participants at Week 9 With a Response in Prostate-Specific Antigen (PSA)

    Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit.

    Time frame: Baseline, Week 9

  2. Median Time to Study Drug Discontinuation

    Exposure to study drug through the data cutoff of 26AUG2011 only. Fifteen participants (25.0%) were still on study drug as of the data cut-off date and were censored at this date.

    Time frame: Duration of study treatment through the data cutoff, up to 3 years.

  3. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 5.

    Time frame: Baseline, Week 5

  4. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 9.

    Time frame: Baseline, Week 9

  5. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 17.

    Time frame: Baseline, Week 17

  6. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 25.

    Time frame: Baseline, Week 25

  7. Change From Baseline in Urinary N-Telopeptide

    Time frame: Baseline, Week 33

  8. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 41.

    Time frame: Baseline, Week 41

  9. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 49.

    Time frame: Baseline, Week 49

  10. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 57.

    Time frame: Baseline, Week 57

  11. Change From Baseline in Urinary N-Telopeptide

    Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 65.

    Time frame: Baseline, Week 65

07

Results

Posted Nov 17, 2014

Participant flow

Single center clinical trial

Participant flow — Overall Study
MilestoneEnzalutamide
Started60
Completed56
Not completed4
Withdrew: Adverse event1
Withdrew: Progressive disease3

Outcome measures

PrimaryChange From Baseline in Bone Marrow Testosterone

Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry.

Time frame:
Baseline, Week 9
Reported as:
Mean · ng/mL
Change From Baseline in Bone Marrow Testosterone
ng/mLEnzalutamide
Change From Baseline in Bone Marrow Testosterone0.05 ± 0.072
SecondaryPercentage of Participants at Week 9 With a Response in Prostate-Specific Antigen (PSA)

Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit.

Time frame:
Baseline, Week 9
Reported as:
Number · percentage of participants
Percentage of Participants at Week 9 With a Response in Prostate-Specific Antigen (PSA)
percentage of participantsEnzalutamide
>=50% Reduction in PSA from Baseline41.1 (28.1 to 55.0)
>=90% Reduction in PSA from Baseline21.4 (11.6 to 34.4)
PrimaryChange From Baseline in Bone Marrow Dihydrotestosterone

Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry.

Time frame:
Baseline, Week 9
Reported as:
Mean · ng/mL
Change From Baseline in Bone Marrow Dihydrotestosterone
ng/mLEnzalutamide
Change From Baseline in Bone Marrow Dihydrotestosterone0.00 ± 0.022
PrimaryChange From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status

Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow testosterone levels at Week 9 was correlated with PSA response status at Week 9.

Time frame:
Baseline, Week 9
Reported as:
Mean · ng/mL
Change From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status
ng/mLEnzalutamide, PSA Responders at Week 9Enzalutamide, PSA Non-Responders at Week 9
Change From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status0.05 ± 0.1070.05 ± 0.034
Statistical analysis
  • Enzalutamide, PSA Responders at Week 9 vs Enzalutamide, PSA Non-Responders at Week 9 · t-test, 2 sided · p = 0.9427 (The p-value was not adjusted for multiplicity.)
PrimaryChange From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status

Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow dihydrotestosterone levels at Week 9 was correlated with PSA response status at Week 9.

Time frame:
Baseline, Week 9
Reported as:
Mean · ng/mL
Change From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status
ng/mLEnzalutamide, PSA Responders at Week 9Enzalutamide, PSA Non-Responders at Week 9
Change From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status-0.01 ± 0.0340.00 ± 0.000
Statistical analysis
  • Enzalutamide, PSA Responders at Week 9 vs Enzalutamide, PSA Non-Responders at Week 9 · t-test, 2 sided · p = 0.3370 (The p-value was not adjusted for multiplicity.)
SecondaryMedian Time to Study Drug Discontinuation

Exposure to study drug through the data cutoff of 26AUG2011 only. Fifteen participants (25.0%) were still on study drug as of the data cut-off date and were censored at this date.

Time frame:
Duration of study treatment through the data cutoff, up to 3 years.
Reported as:
Median · months
Median Time to Study Drug Discontinuation
monthsEnzalutamide
Median Time to Study Drug Discontinuation5.0 (3.6 to 6.0)
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 5.

Time frame:
Baseline, Week 5
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide34.81 ± 137.361
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 9.

Time frame:
Baseline, Week 9
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide205.84 ± 1334.820
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 17.

Time frame:
Baseline, Week 17
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-0.92 ± 205.941
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 25.

Time frame:
Baseline, Week 25
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-18.96 ± 278.112
SecondaryChange From Baseline in Urinary N-Telopeptide
Time frame:
Baseline, Week 33
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-89.36 ± 363.140
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 41.

Time frame:
Baseline, Week 41
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-2.00 ± 22.414
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 49.

Time frame:
Baseline, Week 49
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-2.36 ± 26.526
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 57.

Time frame:
Baseline, Week 57
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide-9.33 ± 37.824
SecondaryChange From Baseline in Urinary N-Telopeptide

Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 65.

Time frame:
Baseline, Week 65
Reported as:
Mean · mmol/mmol creatinine
Change From Baseline in Urinary N-Telopeptide
mmol/mmol creatinineEnzalutamide
Change From Baseline in Urinary N-Telopeptide17.67 ± 17.131

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide—13/60 (21.7%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventEnzalutamide
Urinary tract infectionInfections and infestations2/60
UrosepsisInfections and infestations2/60
Angina pectorisCardiac disorders1/60
Bundle branch block leftCardiac disorders1/60
Myocardial infarctionCardiac disorders1/60
Sinus bradycardiaCardiac disorders1/60
Small intestinal obstructionGastrointestinal disorders1/60
FatigueGeneral disorders1/60
Periorbital cellulitisInfections and infestations1/60
FallInjury, poisoning and procedural complications1/60
Most frequent other events
Showing 10 of 32
Most frequent other events
EventEnzalutamide
FatigueGeneral disorders43/60
AnorexiaMetabolism and nutrition disorders17/60
ConstipationGastrointestinal disorders17/60
ArthralgiaMusculoskeletal and connective tissue disorders16/60
Back painMusculoskeletal and connective tissue disorders14/60
Oedema peripheralGeneral disorders14/60
NauseaGastrointestinal disorders11/60
DyspnoeaRespiratory, thoracic and mediastinal disorders10/60
Hot FlushVascular disorders9/60
Bone painMusculoskeletal and connective tissue disorders8/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Enzalutamide
Mean67.9 ± 9.99
Age, Customized
Age, Customized(years)Enzalutamide
< 556
55 to < 6517
65 to < 7518
>= 7519
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female0
Male60
08

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77303, United States
09

References and documents

Publications

  • Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan;67(1):53-60. doi: 10.1016/j.eururo.2014.05.005. Epub 2014 May 29. PubMed 24882673 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Feb 2012, 24 months.

Results were first posted in Nov 2014, 2 years 8 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 24 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2010
First posted
Mar 23, 2010
StartActual
Feb 18, 2010
Primary completionActual
Feb 29, 2012
CompletionActual
Aug 31, 2013
Results first posted
Nov 17, 2014
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01091103
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Mar 23, 2010
Start date
Feb 18, 2010
Primary completion
Feb 29, 2012
Completion
Aug 31, 2013
Results posted
Nov 17, 2014
Last update
Oct 23, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
Medical Monitor
study director · Medivation, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion